X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs STRIDES PHARMA SCIENCE - Comparison Results

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA STRIDES PHARMA SCIENCE ELDER PHARMA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x -0.2 49.9 - View Chart
P/BV x 0.1 1.1 9.3% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 ELDER PHARMA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
STRIDES PHARMA SCIENCE
Mar-18
ELDER PHARMA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs3801,147 33.1%   
Low Rs188642 29.3%   
Sales per share (Unadj.) Rs491.2317.2 154.8%  
Earnings per share (Unadj.) Rs-3.27.8 -40.6%  
Cash flow per share (Unadj.) Rs14.425.1 57.5%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs376.5274.3 137.3%  
Shares outstanding (eoy) m20.5489.50 22.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.62.8 20.5%   
Avg P/E ratio x-89.3114.0 -78.3%  
P/CF ratio (eoy) x19.735.7 55.2%  
Price / Book Value ratio x0.83.3 23.1%  
Dividend payout %025.5 0.0%   
Avg Mkt Cap Rs m5,83380,058 7.3%   
No. of employees `000NA2.5 0.0%   
Total wages/salary Rs m2,1794,341 50.2%   
Avg. sales/employee Rs ThNM11,325.8-  
Avg. wages/employee Rs ThNM1,731.4-  
Avg. net profit/employee Rs ThNM280.1-  
INCOME DATA
Net Sales Rs m10,08928,394 35.5%  
Other income Rs m257941 27.3%   
Total revenues Rs m10,34629,334 35.3%   
Gross profit Rs m-7923,965 -20.0%  
Depreciation Rs m3611,540 23.5%   
Interest Rs m2,7561,962 140.5%   
Profit before tax Rs m-3,6531,403 -260.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m3,713-436 -851.9%   
Tax Rs m12597 128.6%   
Profit after tax Rs m-65702 -9.3%  
Gross profit margin %-7.814.0 -56.2%  
Effective tax rate %-3.46.9 -49.4%   
Net profit margin %-0.62.5 -26.2%  
BALANCE SHEET DATA
Current assets Rs m9,24024,836 37.2%   
Current liabilities Rs m9,99818,993 52.6%   
Net working cap to sales %-7.520.6 -36.5%  
Current ratio x0.91.3 70.7%  
Inventory Days Days4671 65.3%  
Debtors Days Days60113 52.9%  
Net fixed assets Rs m10,12434,289 29.5%   
Share capital Rs m206895 23.0%   
"Free" reserves Rs m5,58223,651 23.6%   
Net worth Rs m7,73424,546 31.5%   
Long term debt Rs m4,88915,513 31.5%   
Total assets Rs m22,88265,437 35.0%  
Interest coverage x-0.31.7 -19.0%   
Debt to equity ratio x0.60.6 100.0%  
Sales to assets ratio x0.40.4 101.6%   
Return on assets %11.84.1 288.8%  
Return on equity %-0.82.9 -29.5%  
Return on capital %22.36.9 323.6%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m30715,697 2.0%   
Fx outflow Rs m125735 17.0%   
Net fx Rs m18114,962 1.2%   
CASH FLOW
From Operations Rs m11,7541,871 628.3%  
From Investments Rs m-5615,826 -9.6%  
From Financial Activity Rs m-6,762-10,157 66.6%  
Net Cashflow Rs m4,432-2,615 -169.5%  

Share Holding

Indian Promoters % 39.6 27.7 143.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 37.8 19.8%  
FIIs % 16.8 8.6 195.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 25.9 139.4%  
Shareholders   16,479 56,241 29.3%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   DR. REDDYS LAB  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare ELDER PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Prepare to Ride Out Volatile Markets with Rahul Shah(Podcast)

Watching the stock market basically volatile on a regular basis isn't easy. Catch Rahul Shah talk about his mantra to ride out the volatility in times like these.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES SHASUN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Oct 1, 2018 | Updated on Oct 1, 2018

Here's an analysis of the annual report of STRIDES SHASUN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES SHASUN LTD. Also includes updates on the valuation of STRIDES SHASUN LTD.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Why Qualitative Aspects Are So Important To Pick Mutual Funds(Outside View)

Nov 26, 2018

PersonalFN briefly outlines why qualitative parameters are equally important in selecting mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 5-YR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS